Heart Failure

Women are still being excluded from cardiovascular research trials, and it has a lasting impact on heart disease treatment for women today.

UMass Memorial Health–Harrington Hospital reduced 30-day readmissions for congestive heart failure by 50% using artificial intelligence and remote care teams.

Despite being eligible for guideline-directed medical therapy (GDMT), tens of millions of patients across the globe are not receiving the heart failure care they need.

While previous trials have led to questions surrounding the potential benefits of valve interventions in mitral or tricuspid regurgitation, a pair of trials presented recently demonstrate their potential, Javed Butler, MD, MPH, MBA, president of the Baylor Scott and White Research Institute, said.

Inconsistent adherence to the guidelines led to delayed heart failure treatment optimization and underutilization of key therapies.

Hospitals that better utilized heart failure guideline-directed medical therapy (GDMT) had better patient outcomes, with lower mortality rates and costs.

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although the former may provide an edge on quality of life.

Martha Gulati, MD, Cedars-Sinai, discusses the topics expected to be featured at the European Society of Cardiology (ESC) Congress, including a debate she's participating in about the role of hormone replacement therapy (HRT) in primary cardiovascular disease prevention.

New research indicates that the heart benefits of semaglutide can extend to those with heart failure.

Heart failure mortality rates after hospital discharge have seen little improvement since 2010 among Medicare beneficiaries, with real-world outcomes falling short of clinical trial expectations.

A new study found that older patients with atrial functional mitral regurgitation who underwent mitral valve surgery had significantly better outcomes than those who received medical management alone, including lower rates of heart failure hospitalization and death.

The investigational therapy for heart failure (HF) with mildly reduced or preserved injection fraction met its primary end point in the phase 3 trial, Bayer announced.

The catheter-delivered implant uses the right ventricle to support the left, improving left ventricle ejection fraction and helping restore the heart’s normal shape.

A new study revealed longer heart failure hospital stays, better 30-day follow-up, and lower mortality rates in Japan compared with the US.

New studies say restricting salt intake can reduce the risk of atrial fibrillation (AF) in certain patients, but cannot reduce the risks of morbidity and death in patients with heart failure.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, emphasizes the importance of bringing heart health care to patients and meeting them where they are.

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.

It’s important for clinicians to listen to patients and know how heart disease may affect women differently than men, said Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.

Adults aged 70 and older were significantly more likely to develop congestive heart failure if they also experienced olfactory impairment.

According to new research from Jordan, patients with both heart failure (HF) and diabetes had a higher prevalence of HF with preserved ejection fraction (HFpEF), elevated cholesterol, low-density lipoprotein, and impaired kidney function.

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% to 62.5%.

Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight compared with patients taking placebo.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Patients who responded positively to shunt treatment experienced more beneficial changes in their heart's structure and function compared with nonresponders.